Opinion

Video

An Overview of the ARANOTE Trial

A panelist discusses how the ARANOTE phase 3 trial investigated darolutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer, providing an overview of the study design and topline results.

Advanced Prostate Cancer Treatment Strategies

Panel Introduction

Featured Expert:

  • Neal D. Shore, MD, FACS: Medical oncologist and urologist at Carolina Urologic Research Center, Myrtle Beach, South Carolina. Dr Shore is a recognized researcher in urologic oncology with expertise in clinical trials for advanced prostate cancer treatments.

Expert Specialty Areas

  • Urologic oncology
  • Clinical research in metastatic hormone-sensitive prostate cancer (mHSPC)
  • Novel androgen receptor pathway inhibitors
  • Prostate-specific antigen response as predictive biomarker

ARANOTE Trial Overview

Key Themes:

  • Phase 3 clinical trial evaluating darolutamide plus ADT in patients with mHSPC
  • Trial design and methodology
  • Significant efficacy outcomes

Expert Insights:

  • Dr Shore provided an overview of the ARANOTE trial design, which evaluated darolutamide in combination with androgen deprivation therapy (ADT) for patients with mHSPC.
  • The discussion highlighted the topline results demonstrating clinical benefit with this treatment approach.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related Videos
Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
1 expert is featured in this series.
1 expert is featured in this series.
3 experts are featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.